CDK4/6 Inhibition With Anti-PD-1 Checkpoint Blockade Induces Major Response in Aggressive Classic Kaposi Sarcoma After Previous Progression on Anti-PD-1 Alone

JCO Precis Oncol. 2022 Jul:6:e2100550. doi: 10.1200/PO.21.00550.

Authors

Sminu Bose¹, Tristan Lee², Shaelyn Choi¹, Ladan Fazlollahi³, Michael J Rasiej⁴, Gary K Schwartz¹, Matthew Ingham¹

Affiliations

¹ Division of Hematology and Medical Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, NY.
² Department of Medicine, Columbia University Irving Medical Center, New York, NY.
³ Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY.
⁴ Department of Radiology, Columbia University Irving Medical Center, New York, NY.

PMID: 35820086
DOI: 10.1200/PO.21.00550

No abstract available

MeSH terms

Cyclin-Dependent Kinase 4
Humans
Programmed Cell Death 1 Receptor
Sarcoma, Kaposi* / drug therapy
Skin Neoplasms*

Substances

Programmed Cell Death 1 Receptor
CDK4 protein, human
Cyclin-Dependent Kinase 4